← FDA DRUG APPROVALS

FDA NDA · NDA209260

ATROPINE SULFATE

Sponsor: FRESENIUS KABI USA

APPLICATION
NDA209260
TYPE
NDA
ORIGINAL APPROVAL
2018-01-26
LATEST ACTION
2018-01-26
ROUTE
ENDOTRACHEAL, INTRAMEDULLARY, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ATROPINE SULFATE · ReferencePrescription
ATROPINE SULFATE 8MG/20ML (0.4MG/ML) · SOLUTION · INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

Approval history

2018-01-26UNKNOWN · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →